

Datasheet: HCA176G

Description:	HUMAN ANTI TRASTUZUMAB
Specificity:	TRASTUZUMAB
Other names:	HERCEPTIN®
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD16712_hlgG1
Isotype:	IgG1
Quantity:	1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution	Phosphate buffered saline.
Preservative Stabilisers	0.01% Thiomersal
Approx. Protein Concentrations	Antibody concentration 1.0 mg/ml
Immunogen	Trastuzumab (Herceptin®)
RRID	AB_11152942

Specificity **Human anti Trastuzumab, clone AbD16712_hlgG1**, is an anti-idiotypic antibody that specifically recognizes the humanized monoclonal antibody drug trastuzumab, also known as Herceptin®. Clone AbD16712_hlgG can be used to measure the levels of trastuzumab and biosimilar products using bioanalytical assays.

In the HRP-conjugated format clone AbD16712_hlgG1 is ideal for use as a detection antibody in pharmacokinetic (PK) assays. It is a fully human antibody and therefore may also be used as a calibrator in immune response assays to measure the anti-drug-antibody (ADA) response in patient sera.

Trastuzumab is a drug used in the treatment of HER2 positive breast cancer and other HER2 overexpressing cancers including HER2-positive metastatic cancers of the gastrointestinal tract. Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells

[View a summary of all anti-trastuzumab antibodies.](#)

ELISA This product may be used as a detection reagent in a sandwich ELISA, when conjugated to HRP, together with [HCA169](#) as the capture reagent.
Protocol: [PK bridging ELISA to measure free drug](#)
This antibody is fully human and can be used as a reference standard in an ADA assay.
Protocol: [ADA bridging ELISA](#)

References

1. Kashiwagi, N. *et al.* (2017) Method for measuring anti-drug antibody [US Patent Application US20170315118](#)
2. Iwamoto, N. *et al.* (2018) Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis. [Anal Biochem. 540-541: 30-7.](#)

Storage This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee 12 months from date of despatch

Acknowledgements This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Herceptin® is a registered trademark of Genentech, Inc.

Health And Safety Information Material Safety Datasheet documentation #10094 available at:
10094: <https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf>

Licensed Use For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any

form or any other commercial application needs a written agreement with Bio-Rad.

Regulatory For research purposes only

Technical Advice Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#)

Related Products

Recommended Negative Controls

[RECOMBINANT HUMAN IgG1 LAMBDA ALLOTYPED G1m3 \(HCA049\)](#)

Recommended Useful Reagents

[HUMAN ANTI TRASTUZUMAB \(HCA177\)](#)

[MOUSE ANTI HUMAN IgG \(Fc\) CH2 DOMAIN:HRP \(MCA647P\)](#)

[HUMAN ANTI TRASTUZUMAB \(HCA166\)](#)

[HUMAN ANTI TRASTUZUMAB \(HCA169\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[HUMAN ANTI TRASTUZUMAB \(HCA167\)](#)

[HUMAN ANTI TRASTUZUMAB \(HCA168\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M391655:211015'

Printed on 06 Jan 2022

© 2022 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)